Managed Healthcare Executive January 4, 2025
Conventional drug development typically zeroes in on individual proteins or signaling pathways. By focusing on the transcription factor FOXO3, Refoxy hopes to harness a key regulator that impacts numerous biological processes.
Refoxy Pharmaceuticals GmbH, a preclinical biotech firm specializing in age-related disease treatments, has completed a $9.7 million seed-extension financing round which will be targeted towards new treatment options for idiopathic pulmonary fibrosis (IPF).
The financial boost will support the German company’s ongoing development of novel therapeutic agent. With the funds, Refoxy aims to address the complex biology of IPF by targeting the FOXO3 transcription factor, which has the potential to influence multiple biological pathways implicated in disease progression.
FOXO3 is a gene widely recognized for its association with a...
Today's Sponsors
Today's Sponsor